Status: Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Participants needed: 27
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sangamo TherapeuticsUpdated: Jun 1, 2026Locations: 11
Eligibility criteria
Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Ana... [+2]
Persons using opioid analgesics for under 3 months or persons who are not on a s... [+13]